

ASD Care

Food Supplement with microencapsulated Probiotics and Vitamins B5 & B6 with sweeteners
Net weight ≥ 54 g e (30 sticks of 1.8 g each)

WHAT IS ASD CARE?

ASD Care is an orosoluble supplement, combining 5 clinically studied, microencapsulated probiotic strains with Vitamins B5 and B6. GI problems are up to five times more common in neurodivergent groups, with frequent symptoms such as constipation, diarrhoea and abdominal pain¹. Studies also show inflammatory and immune dysregulation^{2,3}.

Gut dysbiosis may contribute to both GI and behavioural issues. The microbiota influences nervous system development⁴, and dysbiosis has been investigated in relation to neurodevelopmental differences.⁵⁻⁷ Changes in the Firmicutes/Bacteroidetes ratio are associated with cognitive and language impairment^{8,9}. Increased intestinal permeability affects 43–76% of individuals¹⁰, and reduced bacterial diversity correlates with worse GI symptoms^{11,12}.

PROBIAL® ASD strains were selected to:

- Reduce Candida and coliforms¹³⁻¹⁶
- Modulate immune responses and oxidative stress¹⁶⁻¹⁹
- Support intestinal permeability¹⁶

In a randomized, double-blind crossover study in 61 children²⁰, 3-month use of PROBIAL® ASD significantly improved behavioural outcomes and GI symptoms, and enhanced beta diversity, indicating strong intestinal colonisation.

WHY CHOOSE ASD CARE?

Microencapsulated for Stability: Probiotics are protected to survive passage through the stomach and reach the gut alive.

Supports Gut Flora Balance: contains ≥ 10 billion live probiotic cultures per stick to promote a balanced intestinal flora. Vitamin B5 contributes to normal energy yielding metabolism, normal mental performance, normal synthesis and metabolism of steroid hormones, vitamin D and some neurotransmitters, reduction of tiredness and fatigue.

Vitamin B6 contributes to normal psychological function and to normal functioning of the nervous system.

Gentle on the senses with pleasant vanilla taste, dissolves directly in the mouth, fast-melt, no water or swallowing required.

INFORMATION ON COMPOSITION

Ingredients: Sorbitol, xylitol, vanilla flavour, silicon dioxide, Probial® ASD microencapsulated probiotic blend : *Limosilactobacillus fermentum* LF10 (DSM 19187), *Ligilactobacillus salivarius* LS03 (DSM 22776), *Lactiplantibacillus plantarum* LP01 (LMG P-21021), *Bifidobacterium longum* DLBL mix (*Bifidobacterium longum* DLBL07 (DSM 25669), *Bifidobacterium longum* DLBL10 (DSM 25672), *Bifidobacterium longum* DLBL11 (DSM 25673)), Vitamin B5 (Calcium pantothenate), Vitamin B6 (pyridoxine hydrochloride), maltodextrin.

ALLERGEN-FREE CERTIFICATION

Certified "allergen-free": contains no gluten, dairy, soy, nuts, eggs, fish, shellfish, or other major allergens.

(*) Excludes products listed in Annex II to Regulation (EU) 1169/2011.

INSTRUCTIONS FOR USE

Children from 4 years and adults: 1 stick per day, preferably on an empty stomach. Pour directly the content of the stick in mouth.

WARNINGS

Do not exceed the stated recommended daily dose. Food supplements should not be used as a substitute for a varied diet. Keep out of the reach of young children. The product contains polyols: an excessive use can have laxative effects. Contains sweeteners.

STORAGE CONDITIONS

The product contains live probiotic micro-organisms sensitive to heat. Keep the product in a cool and dry place, at a temperature between 15–25°C, away from direct light.

DISCLAIMER

This document is intended for informational purposes for consumers and healthcare professionals. Health claims for Vitamins B5 and B6 are authorised by the European Commission. Probiotic benefits refer to support of intestinal flora balance and do not constitute disease treatment claims.

PACKAGING INFORMATION

30 sticks in laminated sachets.

MANUFACTURER

Manufactured by **Probiotal S.p.A.**, Via E. Mattei 3, 28100 Novara, Italy
Distributed by **LIVFE**, 89 Level 0, Triq is-Siggiewi, Siggiewi SGW 2021, Malta – Europe

References:

- 1 Young H, E: Hsiao, EY. Emerging roles for the gut microbiome in autism spectrum disorder. *Biol Psychiatry*, 2017, 81, 411–423.
- 2 Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. *Neuropsychobiology* 2002, 46, 76–84.
- 3 Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: Immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. *Mol, Psychiatry* 2012, 17, 389–401.
- 4 Ma Q, et al. Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. *J Neuroinflammation*. 2019 Mar 1;16(1):53.
- 5 Fond Get al. The "psychomicrobiotic": Targeting microbiota in major psychiatric disorders: A systematic review. *Pathol. Biol.* 2015, 63, 35–42.
- 6 Mayer EA, Paus D, Tillisch K. Altered brain-gut axis in autism: Comorbidity or causative mechanisms? *Bioessays* 2014, 36, 933–939.
- 7 Buie T Potential etiologic factors of microbiome disruption in autism. *Clin Ther* 2015 37:976–983.
- 8 Carlson AL, et al. Infant gut microbiome associated with cognitive development. *Biol Psychiatry* 2018, 83, 148–159.
- 9 Borre Y, et al. Microbiota and neurodevelopmental windows: Implications for brain disorders. *Trends Mol. Med.* 2014, 20, 509–518.
- 10 Emanuele E et al. Low-grade endotoxemia in patients with severe autism. *Neurosci. Lett* 2010, 471, 162–165.
- 11 Kang DW, et al. Reduced incidence of *Prevotella* and other fermenters in intestinal microflora of autistic children. *PLoS ONE* 2013, 8, e68322.
- 12 Finegold SM, et al. Detection of *Clostridium perfringens* toxin genes in the gut microbiota of autistic children. *Anaerobe* 2017, 45, 133–137.
- 13 Deidda F, et al. The in vitro effectiveness of *Lactobacillus fermentum* against broadly used azoles. 2016. *J. Clin. Gastroenterol.* 50: S171–S174.
- 14 Deidda F, et al. How probiotics may kill harmful bacteria: The in vitro activity against some haemolytic strains. *J.Prob. Health*, 2020, Vol. 8 Iss. 2 No: 216.
- 15 Mogna L, et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different *Escherichia coli* strains. *J. Clin. Gastroenterol.* 2012, 46 Suppl: S29–S32.
- 16 Magistrelli L, et al. (2019) Probiotics may have beneficial effects in Parkinson's disease: In vitro evidence. *Front. Immunol.*, 10:969.
- 17 Amoroso, A. et al. (2019) A systematic evaluation of the immunomodulatory and functional properties of probiotic *Bifidobacterium breve* BR03 (DSM 16604) and *Lactobacillus plantarum* LP01 (LMG P-21021). *J. Prob. Health*, 7:214.
- 18 Nicola S, et al. Searching for the perfect homeostasis: Five strains of *Bifidobacterium longum* from centenarians have a similar behavior in the production of cytokines. *J. Clin. Gastroenterol.* Volume 50, Supp. 2, November/December 2016.
- 19 Deidda, F. et al. New approach in acne therapy: A specific bacteriocin activity and a targeted anti-IL-8 property in just one probiotic strain, *Lactobacillus salivarius* LS03. *J. Clin. Gastroenterol.*, 2018 May 18.

